Inhibition mechanism of MRTX1133 on KRASG12D: a molecular dynamics simulation and Markov state model study

Bos JL (1989) Ras oncogenes in human cancer: a review. Can Res 49(17):4682–4689

CAS  Google Scholar 

Simanshu DK, Nissley DV, McCormick F (2017) RAS proteins and their regulators in human disease. Cell 170(1):17–33. https://doi.org/10.1016/j.cell.2017.06.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mo SP, Coulson JM, Prior IA (2018) RAS variant signalling. Biochem Soc Trans 46(5):1325. https://doi.org/10.1042/BST20180173

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pantsar T (2020) The current understanding of KRAS protein structure and dynamics. Comput Struct Biotechnol J 18:189–198. https://doi.org/10.1016/j.csbj.2019.12.004

Article  CAS  PubMed  Google Scholar 

Prior IA, Lewis PD, Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Can Res 72(10):2457–2467. https://doi.org/10.1158/0008-5472.CAN-11-2612

Article  CAS  Google Scholar 

Bourne HR, Sanders DA, McCormick F (1991) The GTPase superfamily: conserved structure and molecular mechanism. Nature 349(6305):117–127. https://doi.org/10.1038/349117a0

Article  CAS  PubMed  Google Scholar 

Wittinghofer A, Scheffzek K, Ahmadian MR (1997) The interaction of Ras with GTPase-activating proteins. FEBS Lett 410(1):63–67. https://doi.org/10.1016/S0014-5793(97)00321-9

Article  CAS  PubMed  Google Scholar 

Gideon P, John J, Frech M et al (1992) Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol 12(5):2050–2056. https://doi.org/10.1128/mcb.12.5.2050-2056.1992

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eccleston JF, Moore K, Morgan L et al (1993) Kinetics of interaction between normal and proline 12 Ras and the GTPase-activating proteins, p120-GAP and neurofibromin: the significance of the intrinsic GTPase rate in determining the transforming ability of ras. J Biol Chem 268(36):27012–27019. https://doi.org/10.1016/S0021-9258(19)74211-2

Article  CAS  PubMed  Google Scholar 

Vetter IR, Wittinghofer A (2001) The guanine nucleotide-binding switch in three dimensions. Science 294(5545):1299–1304. https://doi.org/10.1126/science.1062023

Article  CAS  PubMed  Google Scholar 

Pacold ME, Suire S, Perisic O et al (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ. Cell 103(6):931–944. https://doi.org/10.1016/S0092-8674(00)00196-3

Article  CAS  PubMed  Google Scholar 

Nassar N, Horn G, Herrmann CA et al (1995) The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogue. Nature 375(6532):554–560. https://doi.org/10.1038/375554a0

Article  CAS  PubMed  Google Scholar 

Tuttle RL, Gill NS, Pugh W et al (2001) Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα. Nat Med 7(10):1133–1137. https://doi.org/10.1038/nm1001-1133

Article  CAS  PubMed  Google Scholar 

Drosten M, Dhawahir A, Sum EY et al (2010) Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J 29(6):1091–1104. https://doi.org/10.1038/emboj.2010.7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crespo P, Leon J (2000) Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci CMLS 57(11):1613–1636. https://doi.org/10.1007/PL00000645

Article  CAS  PubMed  Google Scholar 

Marshall C (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80(2):179–185. https://doi.org/10.1016/0092-8674(95)90401-8

Article  CAS  PubMed  Google Scholar 

Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6(3):184–192. https://doi.org/10.1038/nrc1819

Article  CAS  PubMed  Google Scholar 

Kessler D, Gmachl M, Mantoulidis A et al (2019) Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci 116(32):15823–15829. https://doi.org/10.1073/pnas.1904529116

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu K, Li C, Wu KY et al (2022) Modeling receptor flexibility in the structure-based design of KRASG12C inhibitors. J Comput Aided Mol Des 36(8):591–604. https://doi.org/10.1007/s10822-022-00467-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Canon J, Rex K, Saiki AY et al (2019) The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781):217–223. https://doi.org/10.1038/s41586-019-1694-1

Article  CAS  PubMed  Google Scholar 

Nakajima EC, Drezner N, Li X et al (2022) FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res 28(8):1482–1486. https://doi.org/10.1158/1078-0432.CCR-21-3074

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fell JB, Fischer JP, Baer BR et al (2020) Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J Med Chem 63(13):6679–6693. https://doi.org/10.1021/acs.jmedchem.9b02052

Article  CAS  PubMed  Google Scholar 

Hallin J, Engstrom LD, Hargis L et al (2020) The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients therapeutic insight from the KRASG12C inhibitor MRTX849. Cancer Discov 10(1):54–71. https://doi.org/10.1158/2159-8290.CD-19-1167

Article  CAS  PubMed  Google Scholar 

Prior IA, Hood FE, Hartley JL (2020) The frequency of ras mutations in cancer ras cancer statistics. Can Res 80(14):2969–2974. https://doi.org/10.1158/0008-5472.CAN-19-3682

Article  CAS  Google Scholar 

Eser S, Schnieke A, Schneider G, Saur D (2014) Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 111(5):817–822. https://doi.org/10.1158/10.1038/bjc.2014.215

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stephen AG, Esposito D, Bagni RK, McCormick F (2014) Dragging ras back in the ring. Cancer Cell 25(3):272–281. https://doi.org/10.1016/j.ccr.2014.02.017

Article  CAS  PubMed  Google Scholar 

McCormick F (2015) KRAS as a therapeutic target. Clin Cancer Res 21(8):1797–1801. https://doi.org/10.1158/1078-0432.CCR-14-2662

Article  CAS  PubMed Central  Google Scholar 

Wang X, Allen S, Blake JF et al (2021) Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem 65(4):3123–3133. https://doi.org/10.1021/acs.jmedchem.1c01688

Article  CAS  PubMed  Google Scholar 

Hallin J, Bowcut V, Calinisan A et al (2022) Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 10:2171–2182. https://doi.org/10.1038/s41591-022-02007-7

Article  CAS  Google Scholar 

Issahaku AR, Mukelabai N, Agoni C et al (2022) Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. Sci Rep 12(1):17796. https://doi.org/10.1038/s41598-022-22668-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vasta JD, Peacock DM, Zheng Q et al (2022) KRAS is vulnerable to reversible switch-II pocket engagement in cells. Nat Chem Biol 18(6):596–604. https://doi.org/10.1038/s41589-022-00985-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng Q, Peacock DM, Shokat KM (2022) Drugging the next undruggable KRAS allele-Gly12Asp. J Med Chem 65(4):3119–3122. https://doi.org/10.1021/acs.jmedchem.2c00099

Article  CAS  PubMed  Google Scholar 

Hallin J, Bowcut V, Calinisan A et al (2022) Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 28(10):2171–2182. https://doi.org/10.1038/s41591-022-02007-7

Article  CAS  PubMed  Google Scholar 

Mccammon JA, Gelin BR, Karplus M (1977) Dynamics of folded proteins. Nature 267(5612):585–590. https://doi.org/10.1038/267585a0

Article  CAS  PubMed  Google Scholar 

Piana S, Lindorff-Larsen K, Shaw DE (2012) Protein folding kinetics and thermodynamics from atomistic simulation. Proc Natl Acad Sci 109(44):17845–17850. https://doi.org/10.1073/pnas.1201811109

Article  CAS  PubMed  PubMed Central 

留言 (0)

沒有登入
gif